TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB40613

Peptide_Name

Dermaseptin-PP

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 26-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

ALWKDMLKGIGKLAGKAALGAVKTLV-NH2

FASTA

>TPDB40613|Anticancer|length=26
ALWKDMLKGIGKLAGKAALGAVKTLV-NH2

Formula C123H214N32O30S1

Absent Amino Acids RNCEQHFPSY

Common Amino Acids ALK

Mass 2653.31

PI 10.71

Basic Residues 5

Acidic Residues 1

Hydrophobic Residues 15

Net Charge +4

Boman Index 0.46

Hydrophobicity 0.638

Aliphatic Index 131.54

Half Life

Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5500

Absorbance 280nm 207.29

Polar Residues 1

number

5

A

0

R

0

N

1

D

0

C

0

E

0

Q

4

G

0

H

1

I

5

L

5

K

1

M

0

F

0

P

0

S

1

T

1

W

0

Y

2

V

Amino Acid Distribution

A: 5 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 1 L: 5 K: 5 M: 1 F: 0 P: 0 S: 0 T: 1 W: 1 Y: 0 V: 2

Length

26

Formula

C123H214N32O30S1

Mass

2653.31

PI

10.71

Net Charge

+4

Boman Index

0.46

Hydrophobicity

0.638

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Phyllomedusa palliata

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 1.55 µM

Detail Source Activity Anticancer

Activity Measurement 1.55 µM

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.92 µM

Detail Source Activity Anticancer

Activity Measurement 2.92 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4.15 µM

Detail Source Activity Anticancer

Activity Measurement 4.15 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.47 µM

Detail Source Activity Anticancer

Activity Measurement 2.47 µM

Target

Cancer Type Brain Tumor

Cell Line U-251

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Evidence 5 Activity

Activity

Activity Raw

80% LDH release at 10−4 M

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay LDH leakage assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020